The FDA approved leucovorin for a rare disorder without trial data, marking an unusual regulatory decision that could influence how treatments for rare diseases are approved in the future; content creators should note this case as an example of regulatory flexibility and its implications on drug approval processes.
Read the full article at STAT News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
83
Ali NematiWritten by Ali
